The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.
Dapagliflozin does not significantly alter outcomes in patients with or without diabetes who are hospitalized with COVID-19, show the DARE-19 trial findings.